TRESIVAC

Tresivac MMR Vaccine

Tresivac is a vaccine designed to protect against three serious viral infections: measles, mumps, and rubella (MMR). These diseases can lead to severe health complications, including encephalitis (brain inflammation), deafness, infertility, and congenital rubella syndrome, which can cause serious birth defects. Vaccination with Tresivac provides effective protection against these diseases, significantly reducing the risk of outbreaks.

How It Works

Tresivac is a live attenuated vaccine, meaning it contains weakened forms of the measles, mumps, and rubella viruses. These attenuated viruses stimulate the immune system to develop immunity by producing antibodies without causing the actual diseases. This immunity helps protect individuals from future infections if they are exposed to the viruses.

Administration

• Dosage: Tresivac is typically administered as a three-dose series (IAP)
• Schedule:
  • The first dose is usually given at 9 months of age, First booster at 12-15 months of age.
  • The second booster dose is administered at 4-6 years of age, though it can be given earlier, with at least a four-week gap between doses.
• Administration Method: Given as a subcutaneous injection, usually in the upper arm (deltoid region) or thigh.

Side Effects

Common side effects may include:

• Pain, redness, or swelling at the injection site
• Fever
• Mild rash
• Swollen glands in the cheeks or neck
• Temporary joint pain (more common in adults)

Severe reactions are rare.

Pregnancy and Lactation

• Pregnancy: Tresivac is contraindicated during pregnancy. Women of childbearing age should avoid becoming pregnant for at least one month after vaccination.
• Lactation: Safe for breastfeeding mothers, though consultation with a healthcare provider is recommended.

Age Group

• Minimum Age: Approved for use in infants starting at 9 months old (under special circumstances), with the routine schedule beginning at 12 months.
• Upper Age Limit: No strict upper age limit, though it is typically administered during childhood.

Contraindications

• Allergic Reactions: Not recommended for individuals with severe allergies to any component of the vaccine, including neomycin, or to a previous dose of an MMR vaccine.
• Severe Immunodeficiency: Should not be given to individuals with severe immunodeficiency due to conditions such as HIV/AIDS, leukemia, or treatment with immunosuppressive drugs.
• Pregnancy: Contraindicated during pregnancy.

Nature of Antigen

• Nature of Antigen: Tresivac contains live attenuated (weakened) viruses for measles, mumps, and rubella.

Vaccine Type

• Type: Tresivac is a trivalent live attenuated vaccine, meaning it provides protection against three viruses: measles, mumps, and rubella.

Origin and Manufacturer

• Origin: Tresivac is an Indian vaccine.
• Manufacturer: The vaccine is produced by Serum Institute of India, a global healthcare company.
• Introduction Year: Tresivac was introduced in 2008.

Tresivac is an essential vaccine for preventing measles, mumps, and rubella, particularly in children. Developed and produced by Serum Institute of India, Tresivac is widely used in immunization programs around the world. Its safety and efficacy make it a critical component of public health efforts to control these potentially devastating diseases. Always consult healthcare providers for detailed vaccination schedules and personalized advice.